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Abstract
Purpose. This paper describes the clinical history and radiographic appearance of second malignancies in patients with
bilateral retinoblastoma.
Subjects/methods. The imaging studies and clinical data of 14 patients with a history of bilateral retinoblastoma who were
treated for second malignancies were reviewed.
Results. A total of 17 tumors were identi® ed in 14 patients during the period 1978± 1996. The median age of occurrence
of the second malignancy was 17 years (range 10± 32 years). Fourteen of the 17 malignancies occurred in the facial
structures and three developed in the lower extremities. The histologies included osteosarcoma (n 5 5), malignant ® brous
histiocytoma (n 5 3), high-grade spindle cell sarcoma (n 5 3), malignant mesenchymoma (n 5 l), leiomyosarcoma (n 5 4)
and angiosarcoma (n 5 l). The tumors were locally aggressive and had a similar appearance to those found in non-
retinoblastoma patients. Six of the 14 patients are alive and disease free.
Discussion. Most of the adolescent and young adult retinoblastoma survivors developed second malignancies in the
irradiated facial structures but some occurred in distal sites. Radiologically, these tumors do not differ in appearance from
those seen in non-retinoblastoma patients with the exception of their location.
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Introduction
Retinoblastoma (RB) is a rare ocular neoplasm of
childhood which occurs in a sporadic or hereditary
form. While the sporadic form typically presents
with unilateral disease, most patients with the her-
editary form have bilateral retinoblastoma (BRB).
The hereditary form is associated with a germ-line
defect in the retinoblastoma gene, RB-1, on chro-
mosome 13 and is transmitted in an autosomal
dominant pattern. Prognosis for patients with BRB
is excellent with approximately 90% of patients
achieving cure of the primary disease.
1,2 However,
these same patients are at an increased risk of devel-
oping a second malignancy (SM).
3± 5 This paper
summarizes the experience at our institution regard-
ing second malignancies in patients treated for BRB
and describes the radiographic features.
Subjects and methods
A series of 14 patients with BRB presenting with a
SM was obtained via a search of the Memorial
Hospital database. Retrospective analysis of the
charts, pathology and radiologic studies were per-
formed.
Results
A total of 14 patients with BRB were treated for a
second malignancy at our institution during the
period 1978± 1996. Tables 1 and 2 summarize the
clinical history and outcome of these 14 patients.
Thirteen of the patients were diagnosed with BRB
by 21 months of age. One patient (12) is included in
the series because his unilateral RB was multi-focal
and he has a family history of RB. Each patient
initially underwent enucleation of one globe and
most patients had radiation therapy given to the
opposite eye. Two of the patients had radiation
therapy to both eyes. Initial radiation therapy doses
ranged from 3575 cGy to 5400 cGy. The radiation
doses for six of the patients could not be ascertained
as their radiation treatment was performed else-
where. The age at diagnosis of the SM ranged from
10 to 32 years with a median age of 17 years.
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Table 1. Clinical history of nine patients treated for SM after RB
Age at diagnosis
of BRB Age at SM SM in
Patient (months) Treatment of BRB (years) Site of SM radiation port
1 , 12 Enucleation OD 19 Left ethmoid Probable
RT OS: dose?
2 13 Enucleation OD 14 Left orbit Yes
RT OS: 3575 cGy
3 8 Enucleation OS 10 Right maxilla Yes
RT OD: 6900 cGy
4 18 Enucleation OS 19 Left orbit Probable
RT OS: dose?
5 6 Enucleation OS 11 Right orbit Probable
RT OD: dose?
Enucleation OD
6 3 Enucleation OD 16 Left tibia No
RT OS: 3500 cGy 18 Right orbit Yes
7 4 Enucleation OD 13 Left maxilla Yes
RT OU: 4500 cGy
8 9 Enucleation OD 25 Left orbit Yes
RT OS: 5400 cGy
9 11 Enucleation OS 18 Left malar Yes
RT OU: 4500 cGy
10 18 Enucleation OS 12 Right ethmoid Yes
RT 4500: 5000 cGy 14 Upper lip
11 19 Enucleation OS 13 Right femur No
RT 23 Left sphenoid Probable
12 5 RT: 3648 cGy 32 Right ethmoid Yes
13 18 Enucleation OD 20 Left femur No
RT OS
14 21 Enucleation OD 22 Left thigh No
RT OS: 4500 cGy
Enucleation OS
SM 5 second malignancy; RB 5 retinonblastoma; BRB 5 bilateral retinoblastoma; RT 5 radiation therapy; OD 5 right
bone; OS 5 left globe; OU 5 both globes.
Patient 6 was diagnosed with a SM at 16 years of
age, and then developed a third malignancy at age
18 years . This third malignancy, malignant ® brous
histiocytoma (MFH) in the right orbit, was different
in location and histology than the second malig-
nancy, an osteosarcoma of the left tibia.
Patient 10 developed a third malignancy, angio-
sarcoma of the upper lip, 16 months after radiation
therapy for leiomyosarcoma of the right ethmoid
sinus.
Patient 11 developed an osteosarcoma of the
femur 13 years after treatment for BRB and a
leiomyosarcoma within the facial radiation ® eld 22
years after irradiation.
The histologies of the malignancies included ® ve
osteosarcomas (OS), three high-grade spindle cell
sarcomas (HGS), one angiosarcoma, one malignant
mesenchymoma, three malignant ® brous histio-
cytomas (MFN) and four leiomyosarcomas (LMS).
Fourteen of the 17 SM occurred within the facial
structures; six known to be within the radiation
port. In six patients, it is highly likely that the SM
occurred in the radiation port. One patient whose
SM was not in the facial bones ultimately developed
a third malignancy within the radiated facial struc-
tures.
Radiographically, the OS in these patients had a
similar appearance to those in non-BRB patients.
The tumors demonstrated a combination of osteoly-
sis and osteosclerosis and an associated soft tissue
mass. Osteoid matrix was also present (Fig. 1).
Enhancement of these lesions was present on the
contrast-enhanced computed tomography (CT) and
magnetic resonance imaging (MRI) studies. The
location of the OS, however, was unusual. One of
the ® ve OS developed in the long bones (the com-
mon location for de novo OS) while the other four
developed in the facial bones.
The MFH were heterogeneous-enhancing le-
sions which caused osseous destruction which wasSecond malignancies in retinoblastoma 91
Table 2. Outcome of nine patients with SM after RB
Clinical outcome
Patient Site of SM Pathology of SM Treatment of SM (months)
1 Left ethmoid OS Chemotherapy Surgical resection EFS: 91
2 Left orbit OS Chemotherapy D: 27
3 Right maxilla LMS Chemotherapy Radiation therapy D: 16
4 Left orbit HGS Partial resection Chemotherapy ST: 59
5 Right orbit MFH Chemotherapy Surgical resection D: 73
Radiation therapy
6 Left tibia OS Chemotherapy Surgical resection D: 35
Right orbit MFH Chemotherapy Surgical resection
7 Left maxilla OS Chemotherapy Surgical resection EFS: 214
8 Left orbit MFH Chemotherapy Surgical resection D: 98
9 Left malar HGS Chemotherapy Surgical resection EFS: 102
10 Right ethmoid LMS Surgical resection Radiation therapy 24 1
Upper lip Angiosarcoma Surgical resection
11 Right femur OS Chemotherapy Surgical resection 148 1
Left sphenoid LMS Radiation therapy Chemotherapy
12 Right ethmoid LMS Surgical resection Radiation therapy 6 1
13 Left femur HGS Surgical resection 25 1
14 Left thigh Mesenchymoma Surgical resection Radiation therapy 24
SM 5 second malignancy; RB 5 retinonblastoma; OS 5 osteosarcoma; LMS 5 leiomyosarcoma; HGS 5 high-grade
spindle cell sarcoma; MFH 5 malignant ® brous histiocytoma; EFS 5 event-free survival; D 5 decreased; ST 5 surviving with
tumor.
typically permeative. Like the OS, the MFH had an
appearance similar to that of a de novo MFH but the
location was unusual.
The three cases of HGS appeared as inhomo-
geneous masses with central necrosis and contrast
enhancement on MRI and CT. The tumors caused
destruction of the adjacent osseous structures but no
matrix was seen in the soft tissue component. In one
case, patient 4, the HGS started in the left orbit and
caused proptosis of the left globe.
Four patients developed a LMS in our group. This
heterogeneous soft tissue tumor in® ltrated the
paranasal sinuses, and sometimes extended to the
orbit and extended intracranially to destroy the skull
base.
Intracranial extension of the tumor was not un-
common. Three had intracranial tumor at the time
of presentation; patient 5 with MFH, patient 4 with
HGS (Fig. 2) and patient 3 with LMS. Patient 2 may
have had intracranial extension of the OS but the
imaging studies performed prior to treatment were
equivocal. Only one of these four patients, patient 5,
went on to have a complete surgical resection.
While the tumors were frequently large at the time
of presentation, none had metastatic disease at the
time of their initial work-ups. Later in their disease,
patients 3, 5 and 14 developed thoracic metastases
and patient 11 developed abdominal metastatic nod-
ules. Patient 3, initially diagnosed with LMS of the
right maxilla, developed pulmonary nodules. Forty-
four months after treatment of the MFH of the right
orbit, patient 5 had metastatic MFH to the right
pleural space (Fig. 3) and later intrapulmonary dis-
ease.
Nine of the 14 patients in this study experienced
recurrence of their tumors.
Other radiographic features common to these pa-
tients are associated with the therapy they received
Fig. 1. Patient 2, a 14-year-old female, with osteosarcoma of
the left orbit with osseous matrix formation on axial CT. The right
globe has been enucleated.92 C. Z. Rubin et al.
Fig. 2. High-grade spindle cell sarcoma of the left orbit
extending into the middle cranial fossa on an axial T2 weighted
(2500/85) MRI image of patient 4, a 19-year-old female. A
prosthesis is present in the right orbit.
(a)
as treatment for their BRB or SM. Hypotelorism
resulting from radiation-induced bone injury to the
orbit and adjacent bony structures was seen in sev-
eral patients. Cerebral white matter changes from
radiation and chemotherapy were visible on MRI.
Six of the 14 patients have died of causes related
to their malignancies, after surviving a median of 31
months from diagnosis of the SM. Eight patients are
alive, of which six are disease free at a median of 58
months after the SM was diagnosed. Two others are
alive with residual disease.
Discussion
It has been recognized that patients with BRB are at
greater risk of developing a SM. Abramson et al.
determined that two-thirds of the second tumors
arise within the ® eld of radiation therapy and one-
third are outside the ® eld.
2 This suggests that radi-
ation therapy used to treat retinoblastoma may play
a part in the induction of the SM but there must
also be a genetic predisposition. Genetic studies
have demonstrated that the RB-1 gene whose dele-
tion is responsible for retinoblastoma is localized on
band 14 of the long arm of chromosome 13. RB-1
mutations have also been identi® ed in OS.
6± 8
In our study, all the patients received radiation
therapy as part of their treatment for BRB and
developed a sarcoma within the ® eld of radiation.
As with radiation-induced sarcomas in non-RB
patients, the sarcomas developed after a long latency
period. Our patients were diagnosed and treated for
BRB in infancy. The sarcomas which they devel-
oped occurred one to three decades later at a me-
dian age of 17 years with a range of 10± 32 years.
(b)
Fig. 3. Malignant ® brous histiocytoma involving the right
orbit and right pleural space in patient 5, an 11-year-old male.
(a) Heterogeneous soft tissue mass in right orbit causing
destruction of the right ethmoid and right maxilla on coronal
CT scan. (b) Axial CT image of the thorax demonstrating a soft
tissue mass in the right pleural space.
Radiation-induced sarcomas in non-RB patients
have been reported to develop 4± 30 years after
completion of radiation therapy.
10
The doses of radiation used to treat our patients
were in the range which can result in osseous dam-
age. Doses greater than 3000 cGy usually cause
permanent damage to reparative mechanisms while
doses greater than 5000 cGy can cause devitaliza-
tion of bones.
10 These numbers were determined for
adult bones; children may more favorably tolerate
higher doses. Kin et al. reviewed the radiation-
induced sarcomas of bone following therapeutic
radiation at the Memorial Sloan Kettering Cancer
Center from 1977 to 1982.
11 The age of the 10
patients in his study ranged from 9 to 52 years
with ® ve patients under 18 years of age. He found
both osseous and extraosseous sarcomas can de-
velop after receiving doses ranging from 3000 to
6000 cGy, with a median dose of 4605 cGy.Second malignancies in retinoblastoma 93
With the exception of their location, the radio-
graphic appearance of the sarcomas in our patients
was similar to those in non-BRB patients. In our
study, only two of the ® ve OS developed in a long
bone. Typically, OS arise in the metaphyseal region
of the tubular bones with 50± 75% developing
around the knee. Only 5± 10% of de novo OS
develop in the ¯ at bones
12 yet three of the ® ve OS in
our patients developed there.
The tumors were locally advanced at the time of
their presentation and had a propensity to recur,
which may account for the poor clinical outcome for
some of these patients. At our institution, aggressive
treatment for the SM is advocated. Neo-adjuvant
chemotherapy produced responses in the majority of
the patients treated and, with subsequent surgery,
long periods of disease-free survival were obtained.
Six of our 14 patients are alive without evidence of
disease, indicating that apparent cures can be
achieved in a signi® cant minority.
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